Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD6793 with Itraconazole
NCT06494644Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD6793 in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoints: Maximum plasma drug concentration, Area under plasma concentration-time curve from time 0 to last quantifiable concentration and 4 more. Started Jul 2024; status: completed.
02
Drugs
AZD6793
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06494644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494644.